Cammie R. Sutton

Mutant <i>PIK3CA</i> accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies

Ariella B. Hanker, Adam D. Pfefferle, Justin M. Balko et al. · Proceedings of the National Academy of Sciences · 2013 · 194 citations · Full text

Medicine, Cell Biology, Oncology +16

Trastuzumab-Resistant Cells Rely on a HER2-PI3K-FoxO-Survivin Axis and Are Sensitive to PI3K Inhibitors

Anindita Chakrabarty, Neil E. Bhola, Cammie R. Sutton et al. · Cancer Research · 2012 · 136 citations

Medicine, Oncology, Pharmacology +17

An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin

Andrew P. Garner, Carl Uli Bialucha, Elizabeth R. Sprague et al. · Cancer Research · 2013 · 124 citations · Full text

Medicine, Oncology, Pharmacology +12

Dual Blockade of HER2 in HER2-Overexpressing Tumor Cells Does Not Completely Eliminate HER3 Function

Joan T. Garrett, Cammie R. Sutton, M. Gabriela Kuba et al. · Clinical Cancer Research · 2012 · 99 citations · Full text

Medicine, Oncology, Pharmacology +15

Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110α Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers

Joan T. Garrett, Cammie R. Sutton, Richard Kurupi et al. · Cancer Research · 2013 · 87 citations · Full text

Medicine, Oncology, Pharmacology +14